CN1237966C - 一种复方降压制剂 - Google Patents
一种复方降压制剂 Download PDFInfo
- Publication number
- CN1237966C CN1237966C CN 03150916 CN03150916A CN1237966C CN 1237966 C CN1237966 C CN 1237966C CN 03150916 CN03150916 CN 03150916 CN 03150916 A CN03150916 A CN 03150916A CN 1237966 C CN1237966 C CN 1237966C
- Authority
- CN
- China
- Prior art keywords
- group
- indopamide
- content
- converting enzyme
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 59
- 230000036772 blood pressure Effects 0.000 title abstract description 26
- 150000001875 compounds Chemical class 0.000 title abstract description 26
- 239000005541 ACE inhibitor Substances 0.000 claims abstract description 33
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims abstract description 33
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims abstract description 32
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims abstract description 32
- 239000002934 diuretic Substances 0.000 claims abstract description 21
- 230000001882 diuretic effect Effects 0.000 claims abstract description 21
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 33
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 31
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 31
- 239000002876 beta blocker Substances 0.000 claims description 31
- 229940097320 beta blocking agent Drugs 0.000 claims description 31
- 229910001424 calcium ion Inorganic materials 0.000 claims description 31
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 31
- 108010061435 Enalapril Proteins 0.000 claims description 30
- 239000005557 antagonist Substances 0.000 claims description 30
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 claims description 29
- 229960000873 enalapril Drugs 0.000 claims description 29
- 229960000528 amlodipine Drugs 0.000 claims description 26
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims description 26
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 26
- 229960003401 ramipril Drugs 0.000 claims description 25
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims description 25
- 229960002274 atenolol Drugs 0.000 claims description 24
- 239000002131 composite material Substances 0.000 claims description 24
- 229960002237 metoprolol Drugs 0.000 claims description 22
- 229960005425 nitrendipine Drugs 0.000 claims description 22
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 13
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 claims description 8
- 229960002781 bisoprolol Drugs 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- 229960003712 propranolol Drugs 0.000 claims description 8
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims description 7
- 229960004530 benazepril Drugs 0.000 claims description 6
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 6
- 229960001597 nifedipine Drugs 0.000 claims description 6
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims description 5
- 229960000830 captopril Drugs 0.000 claims description 5
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 5
- 229960003580 felodipine Drugs 0.000 claims description 5
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims description 4
- 108010007859 Lisinopril Proteins 0.000 claims description 4
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 229960002490 fosinopril Drugs 0.000 claims description 4
- 229960004340 lacidipine Drugs 0.000 claims description 4
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 claims description 4
- 229960002394 lisinopril Drugs 0.000 claims description 4
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims description 4
- 229960001783 nicardipine Drugs 0.000 claims description 4
- 229960002582 perindopril Drugs 0.000 claims description 4
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 25
- 239000003814 drug Substances 0.000 abstract description 21
- 230000001603 reducing effect Effects 0.000 abstract description 5
- 229960004569 indapamide Drugs 0.000 abstract description 3
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 abstract description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract description 2
- 239000000480 calcium channel blocker Substances 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract 2
- 239000003340 retarding agent Substances 0.000 abstract 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 33
- 229960002003 hydrochlorothiazide Drugs 0.000 description 24
- 230000003203 everyday effect Effects 0.000 description 20
- 238000011282 treatment Methods 0.000 description 19
- 206010020772 Hypertension Diseases 0.000 description 18
- 230000009467 reduction Effects 0.000 description 10
- 238000011287 therapeutic dose Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000035487 diastolic blood pressure Effects 0.000 description 6
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 5
- 102100028255 Renin Human genes 0.000 description 5
- 108090000783 Renin Proteins 0.000 description 5
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 5
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 5
- 239000002220 antihypertensive agent Substances 0.000 description 5
- 229940127088 antihypertensive drug Drugs 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 5
- 229960003147 reserpine Drugs 0.000 description 5
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 5
- 238000011125 single therapy Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000002083 C09CA01 - Losartan Substances 0.000 description 4
- VQKLRVZQQYVIJW-UHFFFAOYSA-N dihydralazine Chemical compound C1=CC=C2C(NN)=NN=C(NN)C2=C1 VQKLRVZQQYVIJW-UHFFFAOYSA-N 0.000 description 4
- 229960002877 dihydralazine Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001077 hypotensive effect Effects 0.000 description 4
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 4
- 229910052753 mercury Inorganic materials 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000019025 Hypokalemia Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 206010047295 Ventricular hypertrophy Diseases 0.000 description 3
- 229960002576 amiloride Drugs 0.000 description 3
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000024896 potassium deficiency disease Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 2
- 101800004538 Bradykinin Proteins 0.000 description 2
- 102400000967 Bradykinin Human genes 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 2
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- -1 atenolol compound Chemical class 0.000 description 2
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940090022 hyzaar Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 229960004773 losartan Drugs 0.000 description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000000955 neuroendocrine Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000036454 renin-angiotensin system Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- BFNXYSZBURSNHS-UVJOBNTFSA-N (2s)-1-[(2s)-6-amino-2-[[(1s)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 BFNXYSZBURSNHS-UVJOBNTFSA-N 0.000 description 1
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- SFIUYASDNWEYDB-HHQFNNIRSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;(2s)-1-[(2s)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O.C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O SFIUYASDNWEYDB-HHQFNNIRSA-N 0.000 description 1
- UIYUUEDFAMZISF-FTBISJDPSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;(2s)-3-methyl-2-[pentanoyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NNN=N1 UIYUUEDFAMZISF-FTBISJDPSA-N 0.000 description 1
- OZCVMXDGSSXWFT-UHFFFAOYSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O OZCVMXDGSSXWFT-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 241000185686 Apocynum venetum Species 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042957 Systolic hypertension Diseases 0.000 description 1
- 108010078660 Vaseretic Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940092576 accuretic Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940092229 aldactone Drugs 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002181 anti-sympathetic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940112147 atacand hct Drugs 0.000 description 1
- 229960003515 bendroflumethiazide Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940003871 calcium ion Drugs 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- JIVPVXMEBJLZRO-UHFFFAOYSA-N chlorthalidone Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-UHFFFAOYSA-N 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229940103463 corzide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 229940074620 diovan hct Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229960000309 enalapril maleate Drugs 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical group OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 229940083558 furosemide 20 mg Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 1
- 229960003602 guanethidine Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940082195 hydrochlorothiazide 12.5 mg Drugs 0.000 description 1
- 229940082205 hydrochlorothiazide 25 mg Drugs 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 229940088024 isoptin Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940080157 lexxel Drugs 0.000 description 1
- 229940080255 lopressor hct Drugs 0.000 description 1
- 229940080266 lotensin hct Drugs 0.000 description 1
- 229940080288 lotrel Drugs 0.000 description 1
- 229940072630 maxzide Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005170 moexipril Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 229940117265 prinzide Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000029547 smooth muscle hypertrophy Effects 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008700 sympathetic activation Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 229940001587 tarka Drugs 0.000 description 1
- 229940015900 tenoretic Drugs 0.000 description 1
- 229940051105 teveten hct Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 229940054506 uniretic Drugs 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940032178 vaseretic Drugs 0.000 description 1
- 229940117978 ziac Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
实施例 | 吲哒帕胺的含量(mg/片) | 血管紧张素转换酶抑制剂、钙离子拮抗剂和β阻滞剂的含量(mg/片) |
1 | 0.25 | 依那普利0.75 |
尼群地平2 | ||
阿替洛尔2.5 | ||
2 | 0.5 | 依那普利1.25 |
尼群地平4 | ||
阿替洛尔5 | ||
3 | 0.75 | 依那普利1.5 |
尼群地平6 | ||
阿替洛尔7.5 | ||
4 | 1 | 依那普利2 |
尼群地平8 | ||
阿替洛尔10 | ||
5 | 1.25 | 依那普利2.5 |
尼群地平10 | ||
阿替洛尔12.5 | ||
6 | 1.5 | 依那普利3 |
尼群地平12 | ||
阿替洛尔15 | ||
7 | 1.75 | 依那普利3.5 |
尼群地平14 | ||
阿替洛尔17.5 |
组别 | 平均剂量mg | 血压mmHg | 治疗结果 | |||
治疗前 | 治疗后 | 达标率% | 有效率% | 无效率% | ||
1.吲哒帕胺组n=80 | 3.5±0.7 | 159.3±15.3/91.9±5.4 | 141.4±16.3/84.3±7.5 | 46.3 | 70.2 | 29.8 |
2.依那普利组n=82 | 12.8±4.3 | 158.9±16.2/91.2±6.6 | 142.4±17.3/85.2±6.4 | 42.2 | 64.7 | 35.3 |
3.尼群地平组n=80 | 35.7±12.4 | 158.8±18.2/90.8±5.6 | 143.1±15.3/84.5±7.4 | 43.4 | 69.4 | 30.6 |
4.阿替洛尔组n=81 | 48.9±11.3 | 160.1±16.8/91.3±7.9 | 142.3±16.2/84.6±5.3 | 40.2 | 65.9 | 34.1 |
5.吲哒帕胺依那普利、尼群地平、阿替洛尔复方制剂组n=82 | 1.2±0.23.0±5.09.6±3.212±4.1 | 160.7±18.1/92.2±7.2 | 127.6±17.9/81.3±7.4 | 72.8 | 91.3 | 8.7 |
P值 | 1∶2∶3∶4∶5>0.05 | 1∶2∶3∶4>0.051∶5<0.012∶5<0.013∶5<0.014∶5<0.01 | 1∶2∶3∶4>0.051∶5<0.012∶5<0.013∶5<0.014∶5<0.01 | 1∶2∶3∶4>0.0511∶5<0.012∶5<0.013∶5<0.014∶5<0.05 | 1∶2∶3∶4>0.011∶5<0.012∶5<0.013∶5<0.014∶5<0.06 |
组别 | 头痛 | 头晕 | 乏力 | 干咳 | 多尿 | 脸红 | 胫踝部水肿 | 心率加快 | 心动过缓 | 口干 | 低钾血 | 高钾血 | 血糖增高 | 总发生率% |
吲哒帕胺组n=80 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 5 |
依那普利组n=82 | 1 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 1 | 0 | 6.1 |
尼群地平组n=80 | 2 | 1 | 0 | 0 | 0 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
阿替洛尔组n=81 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 4.9 |
吲哒帕胺联合依那普利、尼群地平、阿替洛尔组n=82 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.4 |
实施例 | 吲哒帕胺的含量(mg/胶囊) | 血管紧张素转换酶抑制剂、钙离子拮抗剂和β阻滞剂的含量(mg/胶囊) |
9 | 0.25 | 雷米普利1 |
氨氯地平0.5 | ||
美托洛尔7.5 | ||
10 | 0.5 | 雷米普利1.5 |
氨氯地平1 | ||
美托洛尔10 | ||
11 | 0.75 | 雷米普利2 |
氨氯地平1.5 | ||
美托洛尔12.5 | ||
12 | 1 | 雷米普利2.5 |
氨氯地平2 | ||
美托洛尔15 | ||
13 | 1.25 | 雷米普利3 |
氨氯地平2.5 | ||
美托洛尔17.5 | ||
14 | 1.5 | 雷米普利3.5 |
氨氯地平4 | ||
美托洛尔20 | ||
15 | 1.75 | 雷米普利5 |
氨氯地平3.5 | ||
美托洛尔25 |
组别 | 平均剂量mg | 血压mmHg | 治疗结果 | |||
治疗前 | 治疗后 | 达标率% | 有效率% | 无效率% | ||
1.吲哒帕胺组n=32 | 3.6±0.6 | 158.7±14.7/90.8±6.2 | 140.8±15.6/83.7±6.7 | 45.7 | 70.9 | 29.1 |
2.雷米普利组n=32 | 9.8±0.6 | 159.2±15.7/91.1±5.8 | 142.2±16.484.2±5.7 | 42.4 | 63.6 | 36.4 |
3.氨氯地平组n=33 | 7.2±0.5 | 159.3±1525/91.3±6.6 | 140.1±16.1/83.4±6.5 | 46.3 | 70.7 | 29.3 |
4.美托洛尔组n=32 | 68.9±11.3 | 160.2±17.3/90.6±6.7 | 143.4±17.1/84.8±6.3 | 40.8 | 58.7 | 41.3 |
5.吲哒帕胺雷米普利、氨氯地平美托洛尔复方制剂组n=32 | 1.1±0.33.3±0.92.24±0.622.2±6.1 | 161.4±17.7/92.1±8.1 | 125.8±18.3/82.2±6.6 | 73.9 | 88.9 | 11.1 |
P值 | 1∶2∶3∶4∶5>0.05 | 1∶2∶3∶4>0.051∶5<0.012∶5<0.013∶5<0.014∶5<0.01 | 1∶2∶3∶4>0.051∶5<0.012∶5<0.013∶5<0.014∶5<0.01 | 1∶2∶3∶>0.051∶5<0.012∶5<0.013∶5<0.014∶5<0.01 | 1∶2∶3∶4>0.051∶5<0.012∶5<0.013∶5<0.014∶5<0.01 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03150916 CN1237966C (zh) | 2003-09-12 | 2003-09-12 | 一种复方降压制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03150916 CN1237966C (zh) | 2003-09-12 | 2003-09-12 | 一种复方降压制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1522696A CN1522696A (zh) | 2004-08-25 |
CN1237966C true CN1237966C (zh) | 2006-01-25 |
Family
ID=34286811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03150916 Expired - Fee Related CN1237966C (zh) | 2003-09-12 | 2003-09-12 | 一种复方降压制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1237966C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101666757B (zh) * | 2009-09-25 | 2011-03-16 | 广东省药品检验所 | 中草药降压产品中掺杂二氢吡啶类降压化合物的快筛方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100353934C (zh) * | 2004-11-04 | 2007-12-12 | 王睿 | 治疗高血压的复方药物经皮控释给药贴片及其制备方法 |
CN100381122C (zh) * | 2004-12-08 | 2008-04-16 | 北京双鹤药业股份有限公司 | 氨氯地平和阿替洛尔的复方降压制剂 |
CN100384416C (zh) * | 2006-03-20 | 2008-04-30 | 杨军 | 一种用于治疗心血管疾病的药物组合物 |
CN101548985B (zh) * | 2009-05-15 | 2011-05-18 | 赖福平 | 一种复方降压药物及其制备方法 |
CN102008711B (zh) * | 2009-07-14 | 2012-12-26 | 邬林祥 | 一种治疗高血压含依那普利的复方制剂 |
CN105106163A (zh) * | 2015-08-29 | 2015-12-02 | 西安汉丰药业有限责任公司 | 一种含尼可地尔的抗心绞痛药物组合物 |
CN106860417A (zh) * | 2017-04-20 | 2017-06-20 | 上药东英(江苏)药业有限公司 | 一种新的抗心力衰竭疾病的复方缓释片剂及生产工艺 |
-
2003
- 2003-09-12 CN CN 03150916 patent/CN1237966C/zh not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101666757B (zh) * | 2009-09-25 | 2011-03-16 | 广东省药品检验所 | 中草药降压产品中掺杂二氢吡啶类降压化合物的快筛方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1522696A (zh) | 2004-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1651087A (zh) | 有机化合物的联合形式 | |
CN1822820A (zh) | 心血管疾病的治疗和预防 | |
CN1155409C (zh) | 用于预防和治疗动脉硬化的药物组合物 | |
CN101450211A (zh) | 复方降压制剂 | |
CN101080225A (zh) | 包含替米沙坦及氢***的组合治疗 | |
CN1237966C (zh) | 一种复方降压制剂 | |
CN1186097C (zh) | 含有醛糖还原酶抑制剂和ace抑制剂的药物组合物 | |
CN101618215A (zh) | 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物 | |
CN1943564A (zh) | 吲达帕胺缓释片及其制备方法 | |
CN1857726A (zh) | 一种治疗高血压合并高血脂心脑血管疾病的药物组合物 | |
CN1679615A (zh) | 复方小儿能量合剂水溶性维生素制剂及其应用 | |
CN1245160C (zh) | 含吲哒帕胺和血管紧张素转换酶抑制剂的复方降压制剂 | |
CN1225244C (zh) | 含吲哒帕胺和β兼α阻滞剂的复方降压制剂 | |
CN1237971C (zh) | 含血管紧张素转换酶抑制剂、钙离子拮抗剂和艾司***的复方降压制剂 | |
CN1493285A (zh) | 含吲哒帕胺和钙离子拮抗剂的复方降压制剂 | |
CN1493284A (zh) | 含吲哒帕胺和血管紧张素ii受体拮抗剂的复方降压制剂 | |
CN101637609A (zh) | 含氨氯地平、aⅱ受体拮抗剂和他汀类药的药物组合物 | |
CN1899268A (zh) | 苯磺酸左旋氨氯地平滴丸及其制备方法 | |
CN1524523A (zh) | 含吲哒帕胺、血管紧张素转换酶抑制剂和螺内酯的复方降压制剂 | |
CN1864687A (zh) | 复方降压制剂 | |
CN101028518A (zh) | 含有硝酸酯类药物和伊伐布雷定的药物组合物 | |
CN1679608A (zh) | 肌苷、三磷酸腺苷、维生素c复方制剂及其应用 | |
CN103006651B (zh) | 一种含奥美沙坦酯和氨氯地平的片剂及其制备方法 | |
CN1827111A (zh) | 一种以苯磺酸氨氯地平与盐酸贝那普利为活性成分的药用组合物及其制备方法、用途 | |
CN1251673C (zh) | 卡托普利控释制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: DU XIAOFENG Free format text: FORMER OWNER: QIDONG GAITIANLI PHARMACEUTICAL CO., LTD. Effective date: 20110803 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Xu Nantu Inventor after: Du Xiaofeng Inventor before: Xu Nantu |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 226200 NANTONG, JIANGSU PROVINCE TO: 400010 YUZHONG, CHONGQING Free format text: CORRECT: INVENTOR; FROM: XU NANTU TO: XU NANTU DU XIAOFENG |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110803 Address after: 400010, Chongqing, Yuzhong province Jialing East Village No. 49, 2-2 Patentee after: Du Xiaofeng Address before: 226200 No. 88 Heping South Road, Qidong Economic Development Zone, Jiangsu, China Patentee before: Qidong Gaitianli Pharmaceutical Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060125 Termination date: 20190912 |
|
CF01 | Termination of patent right due to non-payment of annual fee |